CSL (ASX:CSL) reaches agreement for COVID-19 vaccine
Jaz Harrison
October 8, 2020
CSL Limited (ASX:CSL) has signed an agreement with the Australian
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
CSL Limited (ASX:CSL) has signed an agreement with the Australian
Share buy-backs have been used by many companies on the
Are big 4 ASX bank shares ‘risky’? Let’s take a
Top performing fund manager, Hyperion Asset Management, recently released an
CSL Limited (ASX:CSL) has revealed that it will manufacture and
In the second installment of our ASX Reporting Season Results
The S&P/ASX 200 (INDEXASX: XJO) is set to take a
CSL Limited (ASX: CSL) shares solidified their position of one
CSL Limited (ASX:CSL) has reported its FY20 report to investors,
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
